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a b s t r a c t
This workshop reviewed the current science to inform and recommend the best evidence-based
approaches on the use of germ cell genotoxicity tests. The workshop questions and key outcomes were
as follows. (1) Do genotoxicity and mutagenicity assays in somatic cells predict germ cell effects? Lim-
ited data suggest that somatic cell tests detect most germ cell mutagens, but there are strong concerns
that dictate caution in drawing conclusions. (2) Should germ cell tests be done, and when? If there is
evidence that a chemical or its metabolite(s) will not reach target germ cells or gonadal tissue, it is not
necessary to conduct germ cell tests, notwithstanding somatic outcomes. However, it was recommended
that negative somatic cell mutagens with clear evidence for gonadal exposure and evidence of toxicity in
germ cells could be considered for germ cell mutagenicity testing. For somatic mutagens that are known
to reach the gonadal compartments and expose germ cells, the chemical could be assumed to be a germ
cell mutagen without further testing. Nevertheless, germ cell mutagenicity testing would be needed for
quantitative risk assessment. (3) What new assays should be implemented and how? There is an imme-
diate need for research on the application of whole genome sequencing in heritable mutation analysis
in humans and animals, and integration of germ cell assays with somatic cell genotoxicity tests. Focus
should be on environmental exposures that can cause de novo mutations, particularly newly recognized
types of genomic changes. Mutational events, which may occur by exposure of germ cells during embry-
onic development, should also be investigated. Finally, where there are indications of germ cell toxicity
in repeat dose or reproductive toxicology tests, consideration should be given to leveraging those studies
to inform of possible germ cell genotoxicity.
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1. Introduction
Fifteen internationally recognized germ cell genetic and
reproductive toxicology experts from government, industry, and
academia, gathered in Foz do Iguacu, Brazil (October 31–November
1, 2013) for an International Workshops on Genotoxicity Test-
ing (IWGT) meeting on advancing the science and regulatory
approaches used to assess mutagenic hazards to germ cells. The
overarching mandate of this workshop was the following: (1)
review the current science; (2) achieve scientific consensus on
issues surrounding the use of germ cell genotoxicity tests in reg-
ulatory assessments; and (3) inform and recommend the best
evidence-based approaches and future prospects in this field. Dis-
cussions and presentations centered on the following topics that
provided a basis for achieving consensus:
• current assays used to assess germ cell mutation;
• regulatory requirements of different countries and interna-
tional organizations for germ cell tests;
• reproductive toxicology assays that can be leveraged for the
assessment of heritable effects;
• assays in need of further development or validation;
• new technologies and approaches;
• the “blood-testis barrier” and pharmacokinetics in male germ
cell toxicity/genotoxicity;
• endpoints most relevant to human genetic risk.
Directed discussions were held on the following key workshop
questions.
(1) Do genotoxicity and mutagenicity assays in somatic cells
predict germ cell effects?
(2) Should germ cell tests be done, and when?
(3) What new assays should be implemented and how?
The workshop resulted in recommendations addressing each of
these questions, with an emphasis on the need to develop improved
methods for germ cell testing, including those that can be inte-
grated with existing genetic and reproductive toxicology tests.
2. Background
Early genetic toxicology focused almost exclusively on heritable
genetic effects. However, in 1973 Dr. Bruce Ames’ seminal paper
[1] that introduced the Salmonella bacterial mutation assay (Ames
test), and other developments, changed the focus of genetic toxi-
cology from germ cells to somatic cells and cancer. The premise that
the majority of carcinogens were somatic cell mutagens and could
be readily detected with short-term assays resulted in a nearly com-
plete shift in focus from heritable genetic hazards to somatic cell
effects. Though, to date, no human germ cell mutagen has defini-
tively been identified, nearly 50 rodent germ cell mutagens are
known [2], and the consequences of heritable mutations remain
of concern.
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BOX 1:
Unique aspects of gametogenesis
• Prolonged developmental and differentiation stages.
• Meiosis.
• Eggs are arrested in prophase 1 of meiosis from birth until
puberty, and do not complete meiosis until fertilized.
• Major morphological changes occur in male germ cell includ-
ing acquisition of motility.
• Haploid.
• Unique chromatin structure.
- In sperm histones are replaced first with transition pro-
teins and then protamines.
- Unique epigenetic sex-specific features occur in the pro-
genitor germ cells and in the early embryo.
• Sperm are DNA repair deficient in the final haploid stages.
• Egg DNA repair machinery in the early embryo is responsi-
ble for repairing damage incurred in the late stage non-DNA
repair proficient spermatids.
Unfortunately, the field has lacked development of new, more
sensitive, less animal-intensive, and higher throughput methods
to detect genotoxic/mutagenic effects in the paternal and mater-
nal germline, and accompanying heritable changes. Indeed, two
of the existing OECD (Organisation for Economic Cooperation and
Development) test guideline (TG) assays that are specific for germ
cell mutations (dominant lethal, and heritable translocation tests,
see Section 3.1 and 3.2 below) require large numbers of rodents
and/or are labor-intensive; as such, they are rarely used. As a result
of the lack of practical and routinely used methods for germ cell
testing, some regulators assume that germline genetic integrity
is protected by default through analysis of somatic cell mutage-
nesis, as discussed recently [3,4]. This assumption has not been
rigorously tested using more recent methodologies, and exceptions
have been noted that show effects occurring to a greater extent in
germ cells or offspring than in somatic cells [5]. Given the unique
aspects of spermatogenesis and oogenesis (see Box 1) it is possi-
ble that there are mechanistic and/or chemical-specific effects to
germ cells not seen in in vivo somatic tests, or in vitro tests. More-
over, given the unique embryogenesis and development of human
female (egg) versus male (sperm) germ cells, and unique milieu of
each, a potential sexual dimorphism for germ cell effects is possi-
ble. In addition to the problems noted above, all the examples of
induced germ cell mutagenicity observed in rodents have not been
confirmed in humans. Thus, extrapolation of rodent germ cell find-
ings to humans for risk assessment has not been applied widely.
A final challenge is that the existing rodent assays capture only a
portion of potential genetic effects; more recent studies applying
powerful new genomics technologies in human clinical genetics
are revealing critical genomic changes associated with genetic dis-
eases that would not necessarily be identified by these traditional
tests. Accordingly, there are limitations and assumptions regarding
current germ cells tests that were focal points of the workshop and
that must be addressed in order to move the field forward.
Despite the lack of optimised tools, regulatory agencies and
expert groups around the world have acknowledged the impor-
tance of identifying germ cell mutagens, and have policies or
practices that require the assessment and management of germ
cell mutagenic hazards. For example, the updated International
Programme on Chemical Safety (IPCS) harmonized scheme for
mutagenicity testing states: “For substances that give positive
results for mutagenic effects in somatic cells in vivo, their potential
to affect germ cells should be considered. If there is toxicokinetic
or toxicodynamic evidence that germ cells are actually exposed to
the somatic mutagen or its bioactive metabolites, it is reasonable
to assume that the substance may also pose a mutagenic hazard to
germ cells and thus a risk to future generations” [6]. Thus, there is
an urgent need to refine the appropriate germ cell tests that should
be conducted and define when they should be used.
Several practical assays have emerged more recently that
address some of the gaps in testing described above: (1) the trans-
genic rodent mutation assays OECD test guideline (TG488) [41]
that includes recommendations for male germ cell mutation anal-
ysis; (2) sperm and pedigree tandem repeat mutation analysis
[7]; (3) improved methods to quantify sperm DNA damage and
chromatin effects [8]; and (4) high-throughput screening for ane-
uploidy in Caenorhabditis elegans eggs [9]. Most importantly, the
rapid technological evolution of genomics tools, including DNA
microarrays and next generation sequencing, is poised to revolu-
tionize the field dramatically. Indeed, whole genome sequencing
has recently been applied to establish that increasing paternal age
in humans is strongly associated with increased transmission of
de novo mutations to offspring [10]; this conclusion is supported
by an increased prevalence of various diseases in the offspring of
older fathers [11]. Findings on paternal age effects extend to global
analysis of microsatellite mutations [12] as well as specific types of
copy number variants (CNV) [13] in humans. Overall, advances in
technologies are a primary reason for the refocus in attention on
germ cell mutagenicity.
The development of new methods to measure germ cell muta-
genicity and the increasing number of human epidemiological
studies that assess markers of germ cell mutagenesis has resulted
in a growing weight of evidence supporting the existence of
human germ cell mutagens (e.g. paternal age, ionizing radiation,
cigarette smoke, chemotherapeutic agents) [10,14–19]. As opposed
to somatic cell mutagenesis, which is generally associated with
carcinogenesis after sufficient functional mutations have accumu-
lated, a single germ cell mutation can potentially lead to an array
of disease phenotypes in addition to being a primary cause of
embryonic and fetal death. Indeed, de novo mutations are now rec-
ognized as contributing to human diseases including neurological
disorders, cancer, and a multitude of other disorders [20–24]. It is
estimated that each human genome contains approximately 100
loss-of-function variants, with as many as 20 of these exhibiting
complete loss of gene function [25]; all of which would have orig-
inated as de novo mutations. Indeed age associated mutations in
sperm are predicted to be of relatively equivalent importance to the
population burden of genetic disease caused by the maternal age
effect on aneuploidy [26]. However, despite such new knowledge,
the contribution of environmental effects to the incidence of de
novo mutations is currently unknown. Nevertheless, de novo germ
cell mutations do contribute to the population burden of genetic
disease, and present a major psychological, emotional, and eco-
nomic burden on societies. Moreover, this analysis provides strong
support for the use of new genomics approaches in identifying the
causes and consequences of germ cell mutations.
Clearly, identification of potential hazards to germ cell genomic
integrity is important in regulatory efforts to protect population
health. These assays must be able to detect chemical agents that
induce the broad spectrum of DNA and chromosome damage
that is documented to occur in germ cells and to be transmit-
ted to offspring. Premutational lesions are transmitted by sperm
and may result in de novo mutations if unrepaired or misre-
paired by egg DNA repair machinery. Additional endpoints include
chromosomal aneuploidies, chromosomal structural aberrations,
CNV, tandem repeat mutations, single nucleotide variants and
insertions/deletions, gene mutations, and mutations in non-coding
sequences. The latter is a particularly important gap as emerging
evidence indicates the importance of non-coding DNA to normal
C.L. Yauk et al. / Mutation Research 783 (2015) 36–54 39
Fig. 1. Depiction of the phases of mouse spermatogenesis, the length of time required from that phase until the sperm is fully mature, and experimental design aimed to
capture exposures during specific cellular phases.
Please note, only male gametogenesis is shown, as the assays described focus virtually exclusively on male germ cells. Female gametogenesis is much more difficult to study
as it occurs once over a prolonged period of time beginning in utero and finishing at fertilization of the mature egg. In addition, there are very few eggs in a mature female
relative to sperm in a mature male, which makes analysis of mutations occurring in eggs much more difficult. Understanding the effects of chemicals on female germ cells
is an important gap in this field.
biological function [27,28]. While epigenetic change in the germline
is an important, rapidly developing area of investigation, it was not
within the scope of this workshop.
3. Current assays used to assess germ cell mutation
The currently available assays for detecting mutations in germ
cells focus primarily on effects in male germ cells because sperm
are more readily accessible and available. Nevertheless, assays for
female germ cells are recognized as an important gap in regu-
latory toxicology testing. Male germ cell assays differ in many
aspects from each other, e.g. in their degree of standardization,
the endpoints detected, and the sensitivity and specificity for
detecting mutagenic chemicals. Male germ cell tests require care-
ful experimental design to ensure that the appropriate phases of
spermatogenesis are tested by waiting specific periods of time
post-exposure prior to sample collection or breeding (Fig. 1). We
briefly discuss regulatory guideline tests that are conducted less
frequently today than in the past, and then we review the more
commonly conducted current assays.
3.1. Heritable translocation and specific locus tests
Until the advent of molecular cytogenetics and genomics tech-
nologies, the gold standards for germ cell testing in the offspring of
exposed parents were the mouse heritable translocation test (HTT,
OECD Test Guideline 485) [29], and the mouse specific locus test
(SLT) [30,31]. The HTT detects genome-wide, chromosomal rear-
rangements that result in sterility or semi-sterility of F1 offspring
of treated males. The SLT detects viable, null mutations at a few
specific loci, which, on a molecular basis, range from base substitu-
tions to deletions spanning beyond the locus itself. The main benefit
of these tests is that they detect genetic changes similar to those
associated with human genetic diseases that are identified in the
offspring of treated parents, demonstrating the actual transmis-
sion of germ cell mutations to the next generation. However, these
assays are extremely time consuming and require very large num-
bers of animals. In addition, the SLT requires the use of a mutant
mouse strain that is homozygous for 7 recessive mutations; this
mouse strain is no longer maintained on a routine basis in any lab-
oratory in the world. For these reasons, the HTT and SLT assays are
no longer performed and are not considered further in this report.
3.2. Dominant lethal test
The dominant lethal test (DLT) measures genetic changes in
germ cells that lead to subsequent embryonic or fetal death (OECD
TG 478) [32,33], and has been the most extensively used germ cell
mutagenicity test. The assay is conducted in either rats or mice,
usually in males. Following paternal exposure, the effects of the
toxicant on the various spermatogenic cell types is tested using
sequential mating intervals with virgin females (e.g. Fig. 1, but usu-
ally mating is done every week for a total of 8 weeks in mice and
10 weeks in rats). Alternatively, males can be treated throughout
an entire cycle of spermatogenesis, with one mating at the end
of the treatment [34]. After an appropriate period of time (e.g. at
mid-gestation or beyond), the ovaries and contents of the uteri of
females exhibiting evidence of mating (i.e. mating plug or presence
of sperm in their vagina) are examined to determine the numbers
of eggs ovulated (via counting corpora lutea) plus the number of
implants and live and dead embryos. Numbers of these events per
female in the treated and control groups are compared to calculate
the dominant lethal effect.
In the DLT, pre- and post-implantation embryonic losses, which
are ostensibly caused by severe structural or numerical chromo-
some changes inherited from exposed fathers, are scored. Several
studies support the chromosomal origin of the embryonic death
[35,36]. While many of the embryonic losses are likely due to
chromosome aberration, gene mutation, and teratogenic effects,
the involvement of cytotoxicity cannot be excluded. Although the
type and location of these lethal genetic changes are not identified,
the DLT is well standardized and, over the years, a considerable
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number of chemicals have been tested using this procedure. Indeed,
the methodology for the test has not changed significantly since
1984 and it is still in use (e.g. [37]). The workshop participants
acknowledged that although the mutational effects are manifest in
the offspring, the endpoint cannot be considered heritable because
the measured outcome is embryonic death; however, the great
majority of chemicals that are positive in the DLT are also positive
in the HTT, which does measure an inherited effect [32,33].
3.3. Cytogenetic analysis of spermatogonia or embryos
The cytogenetic analysis of spermatogonial metaphases [38]
(OECD TG 483) is a standardized method to detect chromosomal
aberrations in male germ cells of mice and rats. The main limitation
of this approach is that possible mutagenic effects are observed at
the beginning of germ cell differentiation; thus, their transmission
to mature gametes and the offspring has not been demonstrated.
The transmission of germline chromosome aberrations to the fer-
tilized egg is detectable by the cytogenetic analysis of first cleavage
zygote metaphases [39]. The application of chromosome paint-
ing has greatly improved the quality and amount of information
that can be obtained by such a test [40], allowing for a distinction
between stable balanced aberrations (e.g. reciprocal translocations)
and unstable aberrations (e.g. acentric fragments, dicentric chro-
mosomes). Comparison of chromosome aberrations in the zygote
with DLT and HTT data following various chemical treatments has
provided evidence to support assumptions on the fate of differ-
ent types of chromosome aberrations [36]. However, only a limited
number of embryos can be collected from each animal, and the
technique for preparing good quality metaphase spreads in the
zygote requires a significant amount of skill, thus hampering wide
dissemination of the approach.
3.4. Transgenic rodent somatic and germ cell mutation assay
The transgenic rodent mutation assay (TGR; OECD TG 488) [41]
is based on mutation detection in a transgenic sequence that can
be rescued from most rodent tissues and expressed in a bacterial
system [42–44]. The TGR assay is amenable to the analysis of tes-
ticular cells and epididymal sperm providing a tool to detect gene
mutations in male germ cells. In addition, mutation spectrum (base
substitutions, insertions/deletions, frameshifts) following chemical
exposure can be determined. Analysis of testicular tissues would
enable the integration of this assay with the standard somatic
cell transgenic mutation assay protocol, significantly reducing cost,
animals and time. However, the sensitivity of the test applied to
cells retrieved from testicular tissues (i.e. cells from a variety of
spermatogenic phases) has not been rigorously tested. This is an
important avenue for future research (discussed in more detail in
Section 10.3), and the test can be improved further by enrichment
for specific germ cell subpopulations from testes prior to mutant
frequency analysis. Although the chemical database for this test in
germ cells is still limited, the approach holds promise for male germ
cell mutagenicity studies because it allows a quantitative com-
parison of the same mutagenic endpoints between somatic and
germ cell tissues [42,44]. However, the potential for using vari-
ations of the transgenic rodent mutation assay to detect female
germ cell mutations is hampered by the vastly insufficient number
of oocytes available per female, which precludes the conduct of the
assay. Therefore, there are no quantitative comparisons of the same
mutagenic endpoints in somatic versus germ cells of females.
3.5. Genotoxicity tests in sperm
Genotoxicity tests in sperm are especially relevant because
they can be applied in both laboratory rodents and humans, thus
providing bridging biomarkers between experimental and biomon-
itoring studies. Different types of pre-mutational and mutational
changes can be detected in sperm, including DNA breaks and aba-
sic sites detectable by the comet assay [45], unscheduled DNA
synthesis (UDS) [46], chromatin packaging alterations detectable
by the sperm chromatin structure assay (SCSA) [47], and numeri-
cal and structural chromosome changes detectable by fluorescent
in situ hybridization (FISH) [48]. These tests could offer potentially
quick, higher throughput pre-screening tools for detecting germ
cell mutagens, even though they do not assess heritable effects.
However, in many cases, protocols have yet to undergo standard-
ization and harmonization processes, and basic science is needed
to identify the mechanisms of induction and the molecular nature
of the detected endpoints. Some of these methods, such as the
comet assay and the SCSA, are applied in the clinical diagnosis and
management of male infertility, which might expedite their stan-
dardization. The most relevant methods are discussed in Section 6
in more detail.
4. Reproductive toxicology and general toxicity assays
capable of providing signals of potential germ cell
genotoxicity
Both reproductive toxicology and repeat dose toxicity studies
may provide signals pertinent to germ cell genotoxicity, and are an
important source of information relating to potential germ cell haz-
ards that has been overlooked in most cases. These studies provide
a wealth of information on reproductive endpoints that can indi-
cate both delivery of the agent to male and female germ cells and
gonadal tissues, as well cytotoxic effects that may occur following
exposure to genotoxicants. A very brief synopsis of the repeat dose
toxicity tests and relevant standard reproductive toxicity tests is
given below.
4.1. Segmented reproductive toxicology designs
Segmented studies expose and assess particular time periods
of development rather than considering the entire life cycle of an
organism all at once. For example, the in utero development of
the fetus may be examined separately from post-natal stages, and
other critical developmental periods, using different exposure and
assessment windows. The International Conference on Harmoniza-
tion (ICH) guideline S5(R2) [49] for the testing of pharmaceuticals,
describes three different segmented designs. The first of these, the
fertility and early embryonic development study, typically begins
exposure 4 weeks prior to mating in males, or 2 weeks in females,
and continues from fertilization through to implantation. The OECD
test guideline 421: reproduction/developmental toxicity screening
test [50] also specifies dosing females for 2 weeks prior to pair-
ing with males that have been dosed for a minimum of 2 weeks.
Unlike the ICH design, this OECD screening study continues dos-
ing of the females throughout gestation and for 4 days postnatally;
therefore, it provides an initial assessment of effects on fertility
and developmental toxicity. Other segmented study designs spec-
ify dosing exclusively during pregnancy. For example, the OECD
prenatal developmental toxicity study (OECD TG 414 [51]) involves
exposure from implantation through to parturition. The next ICH
segment involves exposure of the pregnant dam from implantation
through fetal development (assessing organogenesis), i.e. the ICH
embryo-fetal development study. In the final segmented ICH test,
the pre- and post-natal developmental (PPND) study, administra-
tion to the dam occurs from implantation and through lactation
until pup weaning. These segmented studies are generally not
multi-generational studies.
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Various sampling times are used to assess different develop-
mental outcomes in the fetuses or pups from the above studies.
For example, fetal tissues can be examined to assess morphologic
changes and functional tests, including reproductive performance
testing that can be carried out in the offspring of the exposed dams.
Typically, in utero and lactationally exposed male and female pups
are raised to maturity and mated. The pregnant female is usually
euthanized in mid- gestation to assess effects on fertility and litter
size. In pharmaceutical designs, assessment of the gonads of the
in utero and lactationally exposed F1 is not mandated, nor are any
specific observations made on the F2 fetuses at the mid-gestation
termination.
4.2. Continuous cycle designs
In contrast to segmented designs, continuous cycle designs
cover all of the different stages from germ cell through fetal
development, to adulthood (also known as ‘womb to tomb’).
Most continuous cycle designs evaluate multiple generations, and
exposure spans these generations. The two main approaches for
continuous study designs include the National Toxicology Pro-
gram’s (NTP) reproductive assessment by continuous breeding
(RACB) [52] and the OECD multigeneration study (OECD TG 416
[53]). Various effects are assessed in the F0 that may be relevant to
germ cell mutagenicity, including histopathology on all parts of the
reproductive and endocrine systems. The F0 rodents are mated at
maturity to produce an F1 generation. This mating provides infor-
mation relating to fertility and fecundity in the F0. Effects arising in
the F1 generation, which is also exposed in utero, may be relevant
to potential germ cell effects arising in the F0, but we caution that
effects of exposure in utero cannot be excluded.
4.3. One generation
Various modifications to the multigenerational studies
described above have been developed, including the one-
generation reproduction toxicity study (OECD TG 415 [54])
and the extended one-generation study design (enhanced pre
and postnatal studies) (OECD TG 443 [55]). In the modified
one-generation study rodents are dosed before mating through
gestation. However, the exposure is stopped at various times,
and the rodents are either necropsied for assessment or mated to
produce an F1 generation. The F1 are handled similarly to the F0,
and mating is done to produce F2 pups. Considerations for when
to assess the second generation are discussed in OECD Guidance
Document 117 [56].
4.4. Repeat dose toxicity studies
Repeat dose toxicology study designs can provide information
pertaining to germ cell effects. These include both short-term and
long-term study designs, such as 90 day studies, which can be com-
bined with reproduction/development toxicity screening tests (e.g.
OECD TG 408 and 422 [57,58]). For pharmaceuticals, it is also easy
to combine assessment of male reproductive performance into 3
or 6 month toxicity tests [59]. Various tissues are assessed in these
studies, including germ cells. Ovarian and testicular histopathol-
ogy, sperm count, motility and morphology, can be used to indicate
potential germ cell effects. It is noteworthy that rodent sperm mor-
phology is not generally a sensitive indicator of male reproductive
toxicants and does not correlate with genetic toxicity [60,61]. As
previously described, in general, in repeat dose toxicity tests, it is
easier to use measures assessing the male gonad as indicators for
potential germ cell effects than it is on the female gonad. The end-
points most likely to be affected by genetic damage are fertility and
fecundity, testicular histopathology, testicular weight and sperm
count.
4.5. Opportunities for adapting reproductive and repeat dose
toxicity designs to assess germ cell genetic toxicity
Based on the review of the above toxicology assays, the work-
shop participants recommended specific endpoints from these
assays that should be considered indicative of potential genotoxic
effects to germ cells. The details of this discussion and the recom-
mendations are summarized in Section 10.3.
Overall, it was noted that these assays capture important devel-
opmental stages (e.g. in utero exposure, most of spermatogenesis)
that are not assessed using standard genetic toxicology approaches.
In addition to assessing potential effects that are aligned with toxic-
ity to germ cells across various developmental stages, in both males
and females, the above studies could provide a valuable reposi-
tory of exposed germ cells and pedigrees that can be used as a
source for future genome studies on germ cell mutations and de
novo mutations arising in offspring.
5. Assays in need of further development or validation
A number of additional assays have been developed over the
past decade or more. Many of these assays have been used exten-
sively to measure the effects of germ cell mutagens, but they are in
need of further development and/or validation. A summary of the
advantages and disadvantages of these methods is given in Table 1
and they are described in more detail below.
5.1. Transgenic rodent gene (TGR) mutation reporter assay
As discussed above, the transgenic rodent assay (OECD TG
488) shows great promise in enabling more efficient and effec-
tive screening for chemically induced germ cell mutations. Indeed,
numerous studies have demonstrated the ability of the TGR assay
to detect male germ cell mutagens [42,44]. These studies suggest a
good correlation between mutagens detected with the TGR assay
and the SLT [43]. Moreover, prototypical mutagens exhibit the
expected dose-response in male germ cells for transgene muta-
tions suggesting that the TGR loci respond appropriately and are
representative of effects in other gene regions.
Limitations: There are uncertainties about the optimal experi-
mental protocol for assessing mutagenic effects in germ cells when
integrating germ cell and somatic cell testing. Currently, TG 488
recommends mutation analysis of somatic cells in mice treated for
28 days and euthanized three days after the final exposure (i.e.,
28 + 3d protocol). Also, TG 488 indicates that, for optimal results,
mutations should be evaluated in germ cells sampled from: (a) the
seminiferous tubules in mice from a 28 + 3d protocol; and (b) the
cauda epididymis (i.e. mature sperm) in mice treated for 28 days
followed by a 49 day sampling time (i.e. 28 + 49d). The latter is the
minimum time required for stem cells to produce sperm and is
widely acknowledged to be the standard for accurately evaluating
mutagenic effects in male germline stem cells [39]. Unfortunately,
sampling at two time points effectively doubles the number of ani-
mals and the cost of a study, and restricts opportunities to combine
this assay with other repeat dose studies, leading to a reluctance
among some users to adopt this protocol. Accordingly, it would be
desirable to have only one sampling time for male germ cells (i.e.
the 28 + 3d used for somatic cells).
Sampling at a single time point may be feasible if cells from
the seminiferous tubule at the 28 + 3d time point can be used to
represent various germ cell stages. However, it should be noted
that these cells represent a mixed population that may not be ade-
quately exposed as stem cells at the recommended time point for
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Table 1
Summary of the advantages and disadvantages of existing assays in development or validation stages.
Endpoint Advantages Disadvantages
Transgenic rodent mutation Can be done on most tissues enabling a comparison of
somatic and germ cell sensitivity/specificity, neutral gene,
scores gene mutation, OECD guideline, relatively simple
(integrated into multiple test strategies).
Need transgenic rodents, scores mutations in a non-transcribed
exogenous gene, performed on germ cells not pedigrees thus
inheritance is unclear, may miss some types of mutations.
Tandem repeat assays Endogenous loci, high spontaneous mutation rate, can be
adapted to any species, some markers linked to diseases,
sensitive at low doses, should be able to be integrated into
other tests but validation has not been done.
Unclear indirect mechanism of mutation, non-coding markers,
unclear relevance of tandem repeat mutation to gene mutations,
small dynamic range, some technical challenges.
Spermatid micronucleus (MN) Easily integrated into transgene mutation reporter assay
and other toxicity tests, any species, can be directly
compared to somatic MN to study germ cell
specificity/sensitivity.
Currently laborious (but potential for flow cytometry), small
database, not inherited.
Sperm comet assays Can be done in any species, relatively simple, can be
compared with most somatic cell types, can detect a
variety of DNA damage.
Difficult to integrate with other tests, high variability across
laboratories and studies, biological relevance of endpoint unclear,
technical issues, premutational damage only.
Sperm chromatin structure Fast (flow cytometry approach), can be done in any species
including humans, major validation exercises underway.
Germ cells only, premutagenic lesion (thus implications unclear),
mechanisms causing changes in chromatin unclear, biological and
technical variability results in differences across
studies/laboratories.
somatic tissue analysis (i.e. 28 + 3d); they may not provide the same
sensitivity to detect germ stem cell mutagens as the analysis of
sperm derived from exposed stem cells (i.e. 28 + 49d). Efforts under
the auspices of the Health and Environmental Sciences Institute’s
Genetic Toxicology Technical Committee (germ cell work group)
are generating data to determine whether the analysis of sem-
iniferous tubules at 28 + 3d represent a reasonable compromise.
Preliminary data suggest that analysis of mutations in cells from
seminiferous tubules at 28 + 3d provides an acceptable estimate of
mutant frequencies in stem cells but may greatly underestimate
effects in dividing spermatogonia (Marchetti et al., unpublished
data). Further investigation is needed to determine whether the
28 + 3d protocol provides adequate sensitivity for germ cells, or if
another single sampling time would be more suitable.
TG 488 requires the use of a transgenic rodent model carry-
ing a mutation reporter gene. Such models are limited in use and
availability. The assay is restricted to scoring mutations in a non-
transcribed exogenous gene that is heavily methylated. Although
studies have suggested that care must be taken in extrapolating to
other genomic regions [62], extensive empirical evidence indicates
a high degree of concordance between endogenous and reporter
gene mutation spectra and frequencies [63]. The assay may miss
some types of mutations, including large deletions/insertions for
some TGR loci, and rearrangements or CNVs. While this assay is
performed on germ cells per se, not offspring, potential inheritance
of mutations is inferred. Moreover, the heritability of transgenic
mutations (i.e., the transmission of transgenic lacZ mutations to
offspring) has been demonstrated in one study [64]. Furthermore,
in support of the heritability of TGR mutations, it should be noted
that the TGR germ cell assay detects chemicals that are also positive
in the SLT [43], which supports the inference of a high probability
for the identification of heritable mutations.
5.2. Expanded simple tandem repeat (ESTR) assays
ESTRs consist of long homogenous arrays of relatively short
repeats (4–9 bp) that show a very high spontaneous mutation
rate of length changes both in germline and somatic cells [65].
ESTR loci may be regarded as a class of expanded microsatel-
lites, where the mechanisms underlying spontaneous mutation are
replication-driven [66,67]. The very high spontaneous mutation
rate potentially makes the analysis of length change mutations
occurring at ESTR loci an attractive approach for monitoring
germline mutation induction in mice. Since 1993, these loci have
extensively been used for the analysis of mutation induction in
the germline of male mice exposed to ionizing radiation, chemical
mutagens, and anticancer drugs [68–74], in addition to environ-
mental air pollutants [75–79]. In the early studies, ESTR mutations
were detected using a pedigree-based approach by profiling DNA
samples extracted from all parents and their offspring. Later, a
more sensitive technique using single-molecule PCR was devel-
oped [80] . This approach involves diluting sperm genomic DNA,
and amplifying multiple samples of this DNA (each of which con-
tains approximately one ESTR molecule). This procedure permits
the detection of an indefinitely large number of de novo mutants
in DNA samples extracted from sperm or other cell types. Single-
molecule sperm DNA analysis dramatically reduces the numbers of
mice needed for the measurement of germline mutation frequen-
cies, and the experimental time, by bypassing the need to wait for
mating and birth. Moreover, this approach may be directly appli-
cable to human studies [81–83].
The dose-response of ESTR mutation induction is very close to
that previously obtained using traditional mutation scoring sys-
tems in mice, including the SLT. Statistically significant evidence
for mutation induction is obtained by analyzing hundreds of mice
using ESTRs; whereas, other systems require thousands or even
hundreds of thousands of mice. ESTR mutation rate in the germline
or offspring of male mice exposed to X-rays of fission neutrons
increases linearly with radiation dose [70,71]. An increase in ESTR
mutation rate is detectable at doses substantially lower than can
be monitored by standard genetic techniques in mice. The alkylat-
ing agents ENU and iPMS cause a statistically significant increase
in ESTR mutation rate in the offspring of exposed male mice [74],
and increases in sperm ESTR mutation frequencies occur following
exposure of male mice to commonly used anticancer drugs [73].
Importantly, mutation induction can be measured within the range
of the clinically-relevant doses for humans for anticancer drugs.
Thus, the assay is sensitive and shows great promise for assessing
potential germ cell hazards.
Limitations: The assay scores mutations occurring in a very spe-
cific genomic context: tandem repeats. However, it should be noted
that a growing number of repeat mutations are associated with (or
causative of) human genetic disorders [84].
The mechanisms underlying ESTR mutation induction follow-
ing exposure to ionizing radiation and chemical mutagens cannot
be explained by direct targeting of these small loci by mutagens.
Specifically, the observed increases in ESTR mutation rate in the
offspring and germ cells of exposed male mice are too high to
be attributed to the total number of DNA damaged sites within
these loci. It has been suggested that ESTR mutation induction may
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reflect non-targeted events, where the initial mutagen-related DNA
damage occurring elsewhere in the genome somehow increases
mutation rate at these loci [85]. So, whereas the mechanisms of this
non-targeted process remain unknown, ESTR loci can currently be
regarded as a useful biomarker of exposure to mutagens.
Because all mouse strains carry ESTR loci, the assay can be inte-
grated with standard genetic toxicology tests in mice. However,
mutations occur in replicating cells; thus, the relevant phase of
spermatogenesis must be sampled, which would mean including
an additional set of mice for the ESTR assay for appropriate timing of
sample collection in standard genetic toxicology testing (see Fig. 1).
The ability to score ESTR mutations in testicular cells sampled dur-
ing standard genetic toxicity testing has not yet been investigated
but should be a subject of future research.
The assay requires the PCR amplification of GC-rich repetitive
regions of DNA from very low concentrations, which can be techni-
cally challenging for rodent strains with large alleles. Finally, ESTR
mutation detection requires scoring band length shifts on autora-
diographs, which can be subjective and vary across individuals
and laboratories. This is generally resolved by requiring a generous
shift in size (at least 1 mm), by blinded analyses of samples during
mutation scoring, and by having two individuals score. However,
capillary electrophoresis of smaller repeat loci will permit the anal-
ysis of smaller ESTRs/microsatellites and thus should eliminate any
subjectivity [81]. This should be a focus of future research.
5.3. Spermatid micronucleus (MN) assay
The analysis of induced MN in somatic cells is one of the most
widely used assays in regulatory genetic toxicology testing, and
is the predominant in vivo assay implemented as a follow-up to
positive results in vitro. MN are the product of chromosome dam-
age and/or spindle malfunction, and there are existing OECD test
guidelines for both in vitro (TG 487) and in vivo somatic cell test-
ing (TG 474). The use of the assay has been greatly expanded by
the development of flow cytometry-based methods that allow the
interrogation of thousands of cells, thus providing a high sensitivity
to detect small effects both in vivo [86] and in vitro [87]. There is a
need to have an equivalent assay in germ cells.
An assay for detecting MN in spermatids of rats was devel-
oped in the 1990’s [88]. The assay was subsequently adapted to
detect MN in mouse spermatids and used to investigate the geno-
toxicity of several chemicals. MN detected by this assay originate
during meiosis. About 25 chemicals have been shown to induce sig-
nificant increases in MN in exposed mice, and interestingly, four
of these chemicals (1,1,-dimethylhydrazine, beta-propiolactone,
diethylnitrosoamine and dimethylnitrosoamine) were positive in
spermatids but negative in bone marrow [89]. A previous IWGT
workshop addressed the utility of the MN spermatid assay and its
possible integration with analysis in erythrocytes [90,91]. Although
very little work has been done on this aspect, the MN spermatid
assay is amenable to integration with other genotoxicity tests such
as the recommended experimental design for the transgenic rodent
assay (i.e. 28 + 3d) or within an experiment aimed at assessing lacZ
mutations in sperm and/or seminiferous tubules.
Limitations: The spermatid MN assay is rarely used because it
is labor-intensive, and generally only a few hundred cells per sam-
ple are scored providing limited sensitivity to detect small effects.
Therefore, an automated procedure for scoring MN as is routinely
applied in somatic cells and in vitro should be a focus of future
research. A flow-cytometry based method is being developed in
which spermatids are first isolated by flow sorting based on DNA
content, and then nuclear preparations are analyzed by flow cytom-
etry to detect MN as described for the in vitro MN assay. As in the
somatic cell method, a flow-cytometry approach would allow the
analysis of several thousands of spermatids per sample providing
exquisite sensitivity to detect small effects. Finally, the fate of a
sperm cell carrying MN is unclear, and it is unlikely that these would
be inherited (the same is true of somatic cells). Nevertheless, the
assay provides evidence of genotoxicity in germ cells.
5.4. Sperm comet assay
The comet assay is a simple method for measuring DNA strand
breaks in single cells [92]. The OECD has recently adopted a test
guideline [93] for conducting the in vivo alkaline comet assay to
detect DNA damage. Many chemical and physical genotoxicants
have been analyzed using this protocol both in vivo and in vitro, and
it is generally used to demonstrate a potential for genotoxic hazard
from an exposure [94,95]. Although it has been much more widely
used in somatic cells, the assay has been conducted both on mature
sperm and on germ cells isolated from the seminiferous tubules
[96]. The assay has been applied in numerous studies to demon-
strate induced DNA damage in sperm for exposure to genotoxic
agents [97]
Limitations: During the development of the OECD in vivo
comet assay test guideline, extensive discussions were centered on
whether germ cells should be included. However, it was decided
that the standard alkaline comet assay as described in the test
guideline is not appropriate for measuring DNA strand breaks in
mature germ cells. Three factors were considered in reaching this
conclusion. First, the proposed exposure regimen for the in vivo
comet assay (3 daily doses followed by sample collection 3–6 h
later) is not appropriate for sperm because it represents exposure
of only the fully mature sperm in which the DNA is highly com-
pacted by protamines. At this stage of development, sperm are
extremely resistant to DNA damage [98,99]. Second, analysis of
germ cells collected from the seminiferous tubules is not fully val-
idated yet, and only a few studies have applied this approach [96].
In addition, cells collected from the seminiferous tubules contain
two different germ cell populations (spermatocytes and elongating
spermatids) where DNA double strand breaks are part of the nor-
mal process of development (meiotic recombination for the former,
chromatin compaction in the latter). Slight variation in the propor-
tion of cells that are analyzed between controls and exposed may
produce an apparently significant effect that is coincidental and
not related to chemical exposure. Third, comet analysis in mature
sperm after a prolonged exposure (i.e. 28 days) could provide some
relevant information on whether a chemical induces DNA in germ
cells. The method for the comet assay in sperm is more complicated
than in somatic cells because it requires an enzymatic digestion to
relax the chromatin, and sperm are extremely rich in alkali labile
sites. Because of these factors, it is much more difficult to obtain
reproducible results with mature sperm. Thus, extensive further
validation and development is needed before the comet assay can
be routinely employed for determining whether a chemical induces
DNA damage in germ cells for regulatory purposes. As with other
assays described, the assessment of DNA damage via the comet
assay in germ cells does not detect heritable effects but does pro-
vide evidence of genotoxicity.
5.5. Sperm chromatin quality assays
Surprisingly, assays that assess chromatin quality are in a more
advanced state of validation in humans than in laboratory animals.
Assays are available that assess biomarkers of chromatin integrity
in human sperm such as DNA damage (i.e. breaks and cross-links),
chromatin template function, chromatin structure, and chromatin
epigenome [100]. In addition to the comet assay, the sperm chro-
matin structure assay (SCSA) and the terminal deoxynucleotidyl
transferase-mediated (TdT) deoxyuridine triphosphate (dUTP) nick
end labeling assay (TUNEL) are among the assays most commonly
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Table 2
Summary of the advantages and disadvantages of the newest technologies available to detect germline mutations.
Endpoint Advantages Disadvantages
Copy number variant
analysis using array CGH
and SNP chips
Major phenotypic effects, inherited mutation, relevant to
human genetic disease.
New endpoint with no data in germ cell toxicology, currently
expensive to measure, requires pedigrees, so far not suitable for
measuring somatic mutation in vivo so no direct comparisons can be
made, needs extensive validation for work in toxicology.
Whole genome sequencing Measures broad spectrum of mutations, inherited mutations,
clear linkages to health can be made for certain mutations, any
species including humans.
Expensive, currently requires pedigrees for interpretation (i.e., sperm
analysis not ready yet), bioinformatics challenges, not applied in
toxicology yet (no database), extensive validation still required.
HTS for egg aneuploidy (C.
elegans)
Inexpensive, fast, established model organism in genetics, high
degree of conservation in relevant pathways, detects effects in
female germ cells.
Relationship to humans is unclear, limited to aneuploidy in eggs
measured in embryos at this time, not validated.
used to assess sperm DNA integrity. The SCSA is a flow cytometry
based assay first developed over 30 years ago [8] that measures the
sensitivity of sperm DNA to acid-induced denaturation. The extent
of DNA denaturation is thought to be correlated with the pres-
ence of single stranded DNA and is highly associated with infertility
[101]; thus, it is potentially indicative of genotoxicity. The TUNEL
assay measures DNA breaks in situ as assessed by the incorporation
of dUTP at the sites of breaks [102]. Although these assays gener-
ally correlate well with each other, they measure different aspects
of DNA integrity; therefore, they have different sensitivities. To this
end, an international effort is underway to standardize the comet,
SCSA/acridine orange and TUNEL assays. This initial validation exer-
cise, which involves about 10 established laboratories around the
world, aims to develop fully validated protocols that are sufficiently
robust to assure transferability of the assays across laboratories and
a high degree of data reproducibility. Once validated in humans,
these assays can be readily applied to animal models to provide a
fast and sensitive approach to assess the effects of environmental
exposure on sperm DNA integrity.
Limitations: Although significant research has been conducted
on human sperm DNA integrity over the past decades, our under-
standing of the mechanisms and consequences of sperm chromatin
damage is still incomplete. These assays measure chromatin
changes (i.e. premutagenic lesions) in germ cells only, and it is
not clear what the implications to offspring are. There are indi-
cations that sperm chromatin integrity contributes to healthy
pregnancy and offspring health [103–106]. However, there is still
a lack of consensus on the cut-off values that identify clinically
abnormal parameters. There is also a substantial degree of biolog-
ical and technical variability that can result in differences across
studies/laboratories. The validation exercise for human sperm is
expected to provide guidance on both these current limitations that
are likely to be applicable (with adaptation) to future rodent based
assays.
6. New technologies and approaches
The field of germ cell mutation research is currently under-
going renewed focus predominantly because of the promise of
powerful new genomics technologies. There is a great deal of enthu-
siasm over the opportunities that these new tools bring to the field
[107,108] and abundant applications in the clinic demonstrate their
power in identifying de novo mutations that cause severe human
genetic disorders (e.g. [4,23]). In parallel with increasing sequenc-
ing capabilities, a large amount of effort has been put forth to
develop high-throughput screening (HTS) tools to identify path-
way perturbations [109,110]. HTS is expected to increase chemical
testing capacity and greatly reduce animal use. Given that it is not
currently possible to carry out a full cycle of gametogenesis in vitro,
alternative models must be considered. The potential utility of an
HTS C. elegans model for egg aneuploidy that shows promise is
described below. A summary of the advantages and disadvantages
of the new technologies is provided in Table 2.
6.1. Copy number variants
Research in genomics has led to the discovery that approxi-
mately 12% of human genetic variation is attributed to CNV [111].
CNVs are a type of structural variation that alters, and in many
cases rearranges, the number of copies of specific segments of DNA.
CNVs range in size from 50 base pairs to megabases [112,113]. It is
widely recognized that CNVs account for a broad range of human
genomic disorders [112,114–116]. This can be attributed to the high
mutation rates for genomics rearrangements, which affect >1000-
fold more nucleotides than point mutations [112]. For example, a
genome-wide analysis of CNVs (>100 kbp) in approximately 400
parent- offspring trios found a mutation rate of 1.2 × 10−2 CNVs
per generation [117]. Overall, it is apparent that de novo CNVs
represent an important source of human genetic diversity that con-
tributes to genetic disorders, and is not captured by existing test
methods (for more details see Section 8).
The detection and analysis of CNVs has been greatly facilitated
by the development of high- resolution array comparative genomic
hybridization (or aCGH) and SNP (single nucleotide polymorphism)
microarray technologies [118,119]. These array-based methods are
now being used in the clinic to identify the sources of idiopathic
diseases [120–124] and are the main technologies used to identify
CNVs. However, very little work has been carried out to explore
the effect of mutagens on CNV formation. Work in human cells
in culture has shown that exposure to chemicals causing replica-
tion stress can lead to the formation of CNVs [125–127]. This work
includes exposure to hydroxyurea and aphidicolin, in addition to
exposure to low doses of ionizing radiation (whereby CNVs are
induced through a replication-dependent mechanism, as opposed
to replication-independent repair of double strand breaks). In addi-
tion, increasing paternal age is associated with increases in de novo
CNVs in their offspring through replication-based mechanisms
[12]. However, no single comprehensive study has yet undertaken
an analysis of induced germline CNVs resulting from mutagen
exposure either in an animal model or in humans. Thus, despite
promise, the application of this technology to this field is still in its
infancy.
The workshop participants agreed that research exploring the
effects of mutagens on germ cell CNVs is a critical avenue of
research given the high frequency with which CNVs occur, their
importance in explaining a large proportion of human genetic dis-
ease, and the lack of assessment of CNVs using any of the current
technologies.
Limitations: This technology has yet to be applied in the study of
induced effects in germ cells or somatic cells in vivo. Thus, extensive
development and validation is needed. In addition, the technology
is still expensive, and large sample sizes (>100 offspring per group)
will be required. The technology must be applied to offspring at
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this time, thus parental genomes must be analyzed in addition to
the offspring. The participants acknowledged that this should be an
area of future research focus.
6.2. Whole genome sequencing
The workshop participants generally agreed that next genera-
tion sequencing technologies have matured to a stage where they
can be applied to study the effects of mutagens on heritable germ
cell mutations. The technologies and bioinformatics tools that have
been developed now provide a cost-effective approach to study
induced germ cell mutation in a reasonable time-frame. Proof-of-
concept is provided in a landmark paper by Kong et al. [10], in
which full genome sequencing of 78 Icelandic family trios was used
to demonstrate that males pass on an average of two additional
mutations to their offspring for each year of their reproductive life,
suggesting that the father’s age is a dominant factor determining
the number of de novo mutations in the child. In addition, the
technology is now being used much more routinely in the clinic.
Genome-wide mutation spectra and frequencies in rodent mod-
els should be comparable to humans, and bioinformatics tools can
be used to determine potential phenotypic consequences to the
organism. The recommended strategy to develop the appropriate
sequencing methodologies for applied genetic toxicology is out-
lined in a manuscript published by the ENvironmentally Induced
Germline Mutation Analysis (ENIGMA) working group in 2013 [4].
There was much enthusiasm among workshop participants in the
application of new sequencing tools, and it was recommended that
this be a high priority area for applied research.
Limitations: Despite rapid declines in cost, the technology is
still expensive. However, in contrast to CNVs, smaller sample sizes
should generally be required. The technology currently requires
pedigrees for analysis, increasing the overall number of samples
required and the length of time required. This will be improved
once technologies are available to accurately sequence a sin-
gle gamete genome. Bioinformatics challenges exist that relate
to handling/storing the large amounts of data and applying the
appropriate filters to remove sequencing artefacts without com-
promising sensitivity. Full genome sequencing has not been applied
in toxicology yet and thus there is no existing database. Extensive
validation will be required [4].
6.3. High-throughput analysis of egg aneuploidy in C. elegans
Significant resources are being invested in the development of
HTS tools to identify chemicals that perturb molecular pathways
that are relevant to human and environmental health (e.g., [4,109]).
A major gap in the existing HTS assays is the detection of mutagens
and aneugens. The existing assays are limited to assessing the abil-
ity of a toxicant to initiate a DNA damage response and demonstrate
low sensitivity for identifying mutagens and tumorigens [128]. In
addition, mutagenic effects on germ cells are not considered. The
working group acknowledged the importance of this gap and sug-
gested that some efforts should be focused on determining the best
way to balance the need to understand potential chemical effects on
germ cells with higher-throughput, less animal-intensive method-
ologies.
One assay that partially addresses this gap is a new screening
tool in C. elegans to measure chromosome segregation errors occur-
ring in eggs [129]. Roundworms offer several advantages for this
application because they have a large proportion of germ cells, a
short generation time, and are suitable for culturing in 96-well
plate format. In addition, there is a good degree of conservation
between C. elegans and humans in key meiotic pathways and it is
an established model system in genetics. In the assay, aneuploidy
is examined by observing X-chromosome mis-segregation during
meiosis. Embryos that inherit only one X-chromosome are marked
by the expression of green fluorescent protein under the control
of the X-chromosome counting promoter xol-1. Exposure is per-
formed in 96-well plates, and a 384-well high-content fluorometric
approach is used to score the number of aneuploid embryos. The
assay takes approximately four days, and given the integration of
robotics and culturing in plates, hundreds of chemicals can be ana-
lyzed over a very brief timespan. This high-throughput assay is
followed by other fast assays, such as DNA staining of the germline,
and a germline apoptosis assay, to ensure that aneuploidy origi-
nated from disruption of germline processes.
Although the assay is in its infancy and will require further
validation, preliminary analysis of a selection of 50 chemicals
from ToxCast phase 1 and known chemicals revealed a maximum
balanced accuracy (representing the average of sensitivity and
specificity) of 69% in predicting the ability of chemicals that cause
reproductive toxicity in rodents [9]. The technology was viewed
favorably by the workshop participants, and it was recommended
that this assay be considered for integration with HTS assays as
part of tier 1 screening. It was noted that the model could rela-
tively easily be expanded to apply whole genome sequencing or
CNV analysis. Finally, the assay addresses a critical gap in the field:
measurement of effects on female germ cells.
Limitations: Although there is some degree of conservation in
relevant meiotic and other pathways, the relationship of aneu-
ploidy in C. elegans to the same potential outcome in humans is
unclear. Issues were also raised relating to pharmacokinetic and
dynamic considerations. At this time, the assay is limited to assess-
ing aneuploidy in early embryos.
7. The “blood-testis barrier” and pharmacokinetics in male
germ cell toxicity/genotoxicity
Pharmacokinetic and dynamic parameters are important con-
siderations in toxicological testing to determine the extent of
exposure of particular cell types/tissues. Within the testes, expo-
sure is affected by the presence of the blood-testis barrier that will
result in differential exposures of the various germ cell phases. The
testis presents three possible barriers for blood-borne substances to
reach the germ cells in the seminiferous epithelium (Fig. 2). These
are at the testis vasculature itself, the peritubular myoid cells of
the basement membrane, and the tight junctions of the Sertoli cells
separating the basal and adluminal compartments of the seminifer-
ous epithelium. Although the nomenclature “blood-testis barrier”
is still widely used, unlike the blood-brain barrier, which is actually
at the vasculature, the most effective barrier observed in the testes
is the one formed by the Sertoli cells.
These barriers divide the testes into three compartments. The
interstitial compartment is just outside the vasculature and con-
tains Leydig cells, macrophages, and endothelial cells surrounding
the tubules. The boundary between the interstitial and the basal
compartment of seminiferous tubules is formed by the basal lam-
ina containing peritubular myoid cells. Within the seminiferous
tubules, the basal compartment (containing stem and differentiat-
ing spermatogonia and very early spermatocytes) is separated from
the adluminal compartment (containing the rest of the spermato-
cytes, the spermatids, and the spermatozoa that will be released
into the epididymis and the ejaculate) by occluding junctions
between adjacent Sertoli cells.
Toxicants passing from the testis vasculature into the intersti-
tial compartment cannot be germ cell genotoxicants unless they
also pass through the basal lamina of the seminiferous tubules.
Genotoxicants reaching the basal compartment of the seminiferous
tubules would have a cumulative and permanent effect if they act
on stem cells. In addition they would have an acute, but temporary,
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Fig. 2. Barriers to drug diffusion within testis. Vasculature is indicated in blue, peritubular myoid cells in green, and tight junctions between Sertoli cells in red. (Modified
from Meistrich, M. Brit. J. Cancer, 55: Supl. VI, 89–101, 33).
effect if they act on differentiating spermatogonia; the effect would
remain constant after an exposure time equal to the lifetime of
these cells and not increase under further continuous exposure and
would disappear soon after exposure to the genotoxicant ceases.
The same would hold true for genotoxicants passing through the
Sertoli cell barrier and reaching meiotic and post-meiotic germ
cells, although the lifetime of these cells would be 8 weeks in
human.
Testis capillaries are much more permeable than those in the
brain and contribute little to the blood-testis barrier. Most small
molecules will pass through the testis capillaries at a similar rate as
through capillaries of other tissues, but there is some evidence that
acriflavine (MW 259 Da) has limited diffusion and some proteins
(MW ∼ 30 kDa) have lower concentrations in the interstitial fluid
than in plasma [130].
The peritubular myoid cells form a sheet around the seminif-
erous tubules. In rodents there are occluding junctions between
some but not all myoid cells, but in primates there are no such
junctions. Many small molecules readily penetrate the myoid cell
layer, but proteins (e.g. 44 kDa) only penetrate 15% of tubules
in rodents; however, proteins penetrate all tubules in monkeys
[131,132].
The major barrier to passage of molecules is the tight junctions
between Sertoli cells. It is this barrier that results in the difference in
ionic composition in the fluid in the lumen of seminiferous tubules
(high K+, low Na+) from that of the blood plasma [133]. It also forms
a barrier to small molecules and proteins.
The main factors limiting a molecule’s passage through the Ser-
toli cell barrier are its molecular weight, charge, and hydrophilicity;
lipophilic molecules apparently pass through the cell membranes
and around the junctions more readily. For example, tubular con-
centrations of lipophilic molecules like thiopental (MW 242 Da) will
nearly equal their plasma concentrations within 1 h; whereas, the
hydrophilic molecule inulin (MW 5 kDa) will only reach 2% of the
plasma concentration [134]. A smaller hydrophilic molecule like
urea (MW 60 Da) will reach 70% of plasma concentrations within
the tubular lumen in 1 h. Tubular luminal concentrations of geno-
toxicants like methyl methane sulfonate and busulfan will reach
15%–100% of plasma concentrations in 1 h [135]. Data on DNA
adducts from ethylmethanesulfonate show that it forms adducts
in germ cells at the same level as in bone marrow, and adducts are
detected in late spermatids [136,137].
There are several additional mechanisms affecting the transport
of potential genotoxicants into the tubules and the adluminal com-
partment. For example, active transport or facilitated diffusion with
a carrier brings potassium, iron, testosterone, and GM-CSF into the
adluminal region [138]. On the other hand, cellular efflux proteins
in vascular, peritubular myoid, and Sertoli cells produce partial
protection of germ cells from genotoxicants [139]. Furthermore,
exposure of the testis to toxicants such as busulfan can increase the
porosity of the Sertoli-cell barrier [140], resulting in more exposure
of germ cells to this and other toxicants.
Although stem cells are an important target for cumulative and
permanent genotoxic damage, it is not possible to measure concen-
trations of toxicants in the basal tubule compartment or to isolate
these cells for measurement of damage. Since the peritubular
myoid cells do not form a highly restrictive barrier, measurement
of levels of the toxicant in the testis interstitial fluid will give
an approximation (possibly an overestimate) of the levels at the
stem cells. Killing of the differentiating spermatogonia, which are
extremely sensitive to cytotoxicity from anticancer drugs and alky-
lating agents, or cytogenetic damage to these cells can also be used
as qualitative evidence that a genotoxicant has reached the basal
compartment of the seminiferous tubules.
C.L. Yauk et al. / Mutation Research 783 (2015) 36–54 47
Table 3
Summary of the spectrum of de novo genomic changes occurring in humans and associated tests that can be used to measure them.
Endpoint Relevant genetic toxicology test
Aneuploidy Sperm and egg FISH, spermatocyte and oocyte cytogenetics, pedigree DNA microarray or deep sequencing, spermatid MN.
Structural aberrations Early embryo cytogenetics, sperm FISH, DLT, HTT, some can be identified by pedigree analysis using array CGH, spermatid MN,
spermatocyte cytogenetics.
Copy number variants Pedigree array CGH (microarray) or deep sequencing.
Small molecular rearrangements Array CGH (as small as 500–5000 bp), pedigree deep sequencing.
Small insertions/deletions GPT delta transgene mutation (TGR assay), pedigree sequencing.
Tandem repeat gains/losses ESTR and microsatellite mutation analysis in sperm or pedigrees.
Gene mutations TGR (OECD TG 488), pedigree DNA deep sequencing.
Non-coding mutations Pedigree DNA deep sequencing, CNV analysis.
The post-spermatogonial stages are highly sensitive to muta-
genic effects [141] since they are undergoing meiosis as well as
chromatin remodeling, and they lose DNA repair capabilities. The
simplest way to estimate the dose reaching these cells would be to
measure concentrations of the genotoxicant in the soluble contents
of the seminiferous tubules after removal of the interstitial fluid.
However, there may be some overestimation due to retention of
some of the agent in the small basal compartment of the tubules.
Alternatively, whole testis measurements of the genotoxicant could
be performed with correction for the interstitial fluid concentration
and volume of interstitial space. More difficult, but more precise,
measurements can be done by directly measuring the concentra-
tions in seminiferous tubule fluid; however, measurement of the
rete testis fluid may be an alternative.
This information is important for evidence as to whether or not
a chemical, or its metabolite(s), reaches target germ cells, which
affects the need to conduct germ cell mutagenicity testing.
8. Endpoints most relevant to human genetic risk
Major discussions by the work group were centered on the con-
cept of whether the existing assays (and those in the pipeline)
effectively capture the spectrum of mutational events that both
occur in humans and are relevant to human health. New genomic
tools have allowed for the unprecedented opportunity to assess
genome-wide rates of mutation empirically. A comprehensive
review of the human germline mutational landscape is given in
[112]. Full genome sequencing in human families has been used to
directly measure rates of de novo mutations, demonstrating that
rates of single nucleotide variants (SNVs) range from 1–1.2 × 10−8
SNVs per generation [10,111,142–144], and that 76% of SNVs origi-
nate in the paternal lineage. In contrast to SNVs, both the per locus
mutation rate and the overall number of nucleotides affected per
generation are considerably greater for CNVs [112]. For example,
it has been approximated that one large de novo CNV (>100 kbp)
occurs per 42 births in humans, compared to an average of 61
new SNVs per birth; however, the average number of base pairs
affected by large CNVs is 8–25 kbp per gamete versus 30.5 bp per
gamete for SNVs [117]. Moreover, CNVs are often caused by com-
plex chromothripsis events; these mutations involve multiple de
novo rearrangements in a single event [111,145–147].
In addition to SNVs and CNVs described above, which may
affect coding and non-coding DNA sequences, there are various
other types of important functional genomic changes that arise in
the human genome; these include small insertions and deletions,
mobile element insertions, tandem repeat mutations, translo-
cations and aneuploidies. Microsatellites, in particular, exhibit
proportionally higher de novo mutation rates than SNVs, provid-
ing an important source of genetic variation [12]. Campbell and
Eichler showed that the per generation rates of SNVs, CNVs, mobile
element insertions, and aneuploidy, when contrasted with the
total number of base pairs affected per gamete, demonstrate an
inverse correlation between mutation size and frequency (see Fig. 1
[112]). The figure shows that although more rare, the number of
nucleotides affected by large genomic changes including CNVs and
aneuploidies is orders of magnitude greater. Overall, an analysis of
the rates and spectrum of human mutation reveals a diverse array
of important genomic events that should be considered in genetic
toxicology which are not currently captured in standard genetic
toxicology batteries. Table 3 provides an overview of the endpoints
and considers what assays may be used to assess them.
Finally, it is important to note that human epidemiological stud-
ies have focused on the ability to measure the phenotypic effects
of induced dominant mutations occurring in the descendants of
exposed parents. Recent clinical work using advanced genomics
technologies has revealed that a large proportion of the mutations
occurring in humans are recessive and are not manifest as phe-
notypes for several generations post-origination until conception
occurs with a complementary mutation affecting the same locus
[111], or such a mutation occurs in a somatic cell. This should be
considered in future study designs.
9. Regulatory requirements for germ cell tests worldwide
Strategies and guidelines for regulatory toxicology testing in
various national regulatory jurisdictions, including requirements
for germ cell mutation assays, were described extensively by
Cimino [148], and have not changed significantly. No jurisdiction
requires germ cell testing in an initial test battery (e.g. Tier 1 below).
Genetic toxicology testing strategies across regulatory agencies
can generally be separated into three tiers. Tier 1 contains required
in vitro and somatic in vivo tests; while, tiers 2 and 3 contain germ
cell tests that can be requested for follow-up studies, under cer-
tain conditions in many regulatory authorities, e.g. in the U.S.A.
(U.S. EPA and U.S. FDA), Canada (Health Canada), the United King-
dom (Committee on Mutagenicity: COM), and Europe (Registration,
Evaluation, Authorization and Restriction of Chemicals: REACH).
DNA damage assays in the testes or spermatogonia fall into tier 2;
whereas, tier 3 assays involve germ cell mutation tests. India and
Australia use only tier 1 assays; therefore, they do not require any
germ cell assays for regulatory purposes. Other countries generally
follow strategies similar to the U.S. EPA guidelines for industrial
chemicals. For pharmaceuticals, the ICH Technical Requirements
for Registration of Pharmaceuticals for Human Use does not require
germ cell tests and assumes that in vivo somatic tests and car-
cinogenicity data will provide sufficient predictivity/protection for
germ cell effects [149].
As described by Eastmond et al. [6], the World Health Organi-
zation (WHO)/IPCS Harmonized Scheme notes that if an agent is
positive in vivo for somatic cell mutation, then that agent can be
considered, or requested, for testing for germ cell mutations; how-
ever, such testing is not required. In addition, WHO/IPCS identifies
the following as suitable assays in germ cells: transgenic mouse
models, the ESTR assay, the spermatogonial chromosome aberra-
tion assay, chromosome aberration analysis by FISH, the comet
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Table 4
Categorization of mutagens by OECD/GHS/ECHA.
Unique aspects of gametogenesis
Category Description
1A Chemicals known to induce heritable mutations in
germ cells of humans
1B Chemicals that should be regarded as if they induce
heritable mutations in germ cells of humans
2 Chemicals that cause concern for induction of
heritable mutations in germ cells of humans
assay, and assays for DNA adducts. The WHO/IPCS tests in offspring
include the ESTR assay, the DLT, the HTT, and the SLT.
The Global Harmonization Scheme (GHS) [150] identifies muta-
gens according to the categories noted in Table 4. To date 67
countries have implemented this programme and are in the process
of integrating it into their relevant regulations. Within the Euro-
pean REACH strategy an agent that is genotoxic in somatic cells
is evaluated from the literature to see if it is a potential germ cell
mutagen based on bioavailability to the germ cells and appropri-
ate in vivo data. If such an evaluation shows that the literature is
insufficient to determine whether the agent is or is not a poten-
tial germ cell mutagen, then that agent can be tested in a suitable
germ cell genotoxicity assay. Although germ cell testing is not
specifically required under the Canadian Environmental Protec-
tion Act (CEPA) New Substances Notification Regulations, germ cell
mutation tests are requested and evaluated when necessary. For
assessments under the New Substance Program from 1994 to 2012,
a total of 19 chemicals have been evaluated for germ cell muta-
genicity (12 for which the test was submitted, plus 7 for which the
test was referenced on the MSDS); this is comparable to the num-
ber for which testing in rodent cancer assays was evaluated (i.e.
total of 20:17 for which the test was submitted, plus 3 for which
test was referenced on the MSDS) (Personal Communication, New
Substances Assessment and Control Bureau, Health Canada).
In summary, germ cell mutation is a regulatory endpoint for
many organizations, including the IPCS, the regulatory agencies
in the U.S., Canada, U.K., and European Union (E.U.). Germ cell
mutagens are classified in a manner analogous to that of carcino-
gens by IARC by Health Canada, GHS, European Chemical Agency
(ECHA), and the German Commission for Occupational Health
(MAK). Although germ cell mutation is an established regulatory
endpoint, the appropriate assays exist, and more than 50 agents
have been identified as germ cell mutagens in rodents, no agent
has yet to be regulated solely as a germ cell mutagen, or evaluated
to be a human germ cell mutagen. As data accumulate showing
that cigarette smoke, air pollution, and ionizing radiation are likely
human germ cell mutagens, this situation is expected to change
soon [2].
10. Discussion
The following questions were discussed at the IWGT work-
shop. Unless indicated otherwise, a consensus was achieved on the
resulting statements below.
10.1. Do genotoxicity and mutagenicity assays in somatic cells
predict germ cell effects?
To address this question, the workshop participants revisited
a retrospective analysis that was undertaken to assess the per-
formance of selected short-term tests in the discrimination of
mammalian germ cell mutagens and non-mutagens [151]. The
analysis considered 1080 references with results on germ cell
mutagens, and 911 references with results on germ cell non-
mutagens. Based on the primary literature available at the time,
23 multi-test, confirmed germ cell mutagens were identified (7
additional chemicals were positive only in a single replicated test).
All 23 mutagens were positive in the DLT (15 in mouse, 1 in rat,
and 7 in both mouse and rat). Twenty-one multi-test, confirmed
germ cell non-mutagens were identified (6 more were negative
only in a single replicated test). All 21 chemicals were confirmed
negative in the DLT (11 in mouse, 2 in rat and 8 in both). The
report suggested the value of the mouse bone marrow MN test
as an assay that is predictive of potential germ cell mutagenicity
based on mouse DLT results (as confirmation of germ cell dam-
age). Furthermore, regression analysis of the lowest effective doses
tested in the two assays demonstrated that the mouse MN test
responded at a lower dose than the mouse DLT. Overall, a high
degree of sensitivity was found (>90%) for the prediction of germ
cell mutagenicity from mouse MN in somatic cells, but it was
noted that this may be due to the type of chemicals considered.
Specificity was much lower (63–64%), indicating that a propor-
tion of chemicals that was not positive in the DLT was positive
in the MN assay in somatic cells. Unfortunately, a more adequate
database does not exist at present, and no more recent analyses
have been conducted. The current database has some limitations.
(a) It is biased towards chemicals that were first found positive in
a somatic cell test and is skewed towards alkylating agents. (b) It
is limited to a few specific mutational mechanisms or mutation
types including SNVs and larger scale chromosomal rearrange-
ments. (c) The database does not include the more recent OECD
TG 488 data or other newer germ cell tests. (d) Data are deficient
in recently recognized endpoints like CNVs. (e) Lastly, the database
contains a number of qualitative and quantitative exceptions as
follows: (i) dominant lethal mutations following acrylamide expo-
sure and germ cell tandem repeat mutations following exposure
to mainstream tobacco smoke occur in the absence of significant
increases in bone marrow or blood MN [5,75]; (ii) four chemicals
(1,1-dimethylhydrazine, beta-propiolactone, diethylnitrosoamine
and dimethylnitrosoamine) were negative in the bone marrow MN
assay, but were found to be positive in the spermatid MN assay
[89]; and (iii) three agents, MMS, acrylamide, and ionizing radia-
tion showed quantitatively greater clastogenicity in exposed sperm
(detected as chromosomal aberrations in zygotes) than in bone
marrow of mice [152–156].
Overall, the workshop participants acknowledged that based
on the available (limited) data, somatic cell tests appear to pre-
dict germ cell effects quite well but with relatively low specificity.
However, there are notable exceptions and of particular concern is
the broad spectrum of new mutational endpoints that are emerg-
ing as critical to human health that are not captured by existing
tests. Accordingly, caution should be exercised at present in draw-
ing broad conclusions around the question of the predictivity of
somatic in vivo tests for mutagenic effects in germ cells. More work
needs to be done to expand the available database to include the
most relevant tests and endpoints, to understand the prevalence
of exceptions, as well as to expand beyond the presently biased
chemical space covered in the database, prior to drawing a firm
conclusion on this question. Finally, it was suggested that retro-
spective analyses be conducted that consider more quantitative
metrics (e.g. mathematical models to derive points of departure –
see more details in Section 11). Such refined quantitative analyses
can provide more information on the low end of the dose-response
curve to yield an improved understanding of the toxicological sen-
sitivity of germ cells versus somatic cells, and to determine if there
are true hazards for heritable effects based on animal data.
10.2. Should germ cell tests be done, and when?
As with other target tissues, if there is no significant risk that
humans or their germ cells will be exposed, then there is no need for
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germ cell testing. Furthermore, in accord with the approach in the
OECD test guidelines for somatic in vivo tests, if there is evidence
that a chemical, or its metabolite(s), will not reach target germ cells
or gonadal tissue, it is not appropriate to conduct germ cell tests
with either in vivo positive or negative somatic mutation outcomes.
However, because of uncertainties discussed regarding the predic-
tivity of somatic cell assays, it was recommended by a very large
majority that negative somatic cell mutagens with clear evidence
for gonadal exposure and evidence of toxicity in germ cells could
be considered for germ cell mutagenicity testing, which would also
serve to fill critical data gaps. Signals of concern from repeat dose
toxicity tests and reproductive toxicity tests include germ cell loss
in testicular histopathology or decreased sperm counts, any evi-
dence of reduced fertility and/or implant loss in mating studies, and
especially increased post implantation losses. For somatic muta-
gens that are known to reach the gonadal compartments and result
in the exposure of germ cells, a large majority agreed that it could
be assumed that the test substance is likely a germ cell mutagen
without further testing. Nevertheless, germ cell mutagenicity test-
ing would still be needed if quantitative germ cell risk assessment is
required, since there are data indicating that germ cell effects occur
at lower doses than somatic cell mutagenicity, or within endpoints
not currently studied in somatic cells.
It was noted that the male germ cell compartment is rarely
included in PB/PK studies. The group recommends that more con-
sideration be given to germ cell exposure, and that male germ cell
compartment should become part of the PB/PK measurements or
modelling.
10.3. What new assays should be implemented and how?
This discussion expanded to include various points relating to
what assays should be recommended as we move forward. Clearly,
there are existing assays that need further development/validation
as well as new assays that can be recommended as previously
discussed. The workshop also considered what existing reproduc-
tive toxicology assays should be used to identify potential germ
cell hazards, which is a shift in thinking in this field. In addi-
tion, within these discussion points, the participants recommended
what assays should be integrated with existing tests.
10.3.1. Germ cell genotoxicity/mutagenicity tests
Based on discussions pertaining to the limitations of existing
assays and the human mutational spectrum assessed by these
assays, the participants noted that there is an immediate need for
research on the application of whole genome sequencing in her-
itable mutation analysis and for genome wide assays of de novo
mutational events (both SNV and CNV). The group agreed that
integration of whole genome sequencing with existing assays is
best facilitated through reproductive toxicology testing (see Sec-
tion 10.3.2 for this discussion). The egg aneuploidy assay in C.
elegans was also endorsed as a promising avenue for tier 1 high
throughput screening.
However, in parallel with the application of these new assays,
there is a perceived, immediate need for the currently available
germ cell tests to be integrated with somatic cell genotoxicity tests
to address gaps in this field. Specifically, it was recommended that
further research is needed to develop an integrated approach for
the TGR assay (to assess both somatic and male germ cell mutation
concurrently), and the spermatid MN assay (with the somatic cell
MN test). The integration of germ cell gene mutation analysis using
the TGR assay (TG 488 [41]) was noted as a particular opportu-
nity to expand our existing database of knowledge relating to germ
cell versus somatic cell effects. A large majority of participants felt
that it should be recommended that the relevant germ cell tests be
run routinely in parallel with somatic cell tests when conducting
transgenic mutation studies. Objections to this were based on the
need to have a stronger database before this recommendation can
be made (thus, requiring more research). Some discussion also cen-
tered on the possibility of capturing more endpoints of relevance
by analyzing clastogenicity within the same TGR animals. A large
majority of participants recommended the use of the spermatid
MN assay for this purpose; they also felt that a germ cell chromo-
somal aberration assay should be carried out in parallel with bone
marrow chromosome aberration assays. Finally, given the rapid
pace of implementation of sperm chromatin damage assays in the
clinic, a general need exists to standardize the protocols for the
sperm comet assay, TUNEL and the SCSA to provide readily compa-
rable rodent and human data. There was consensus that integration
of these tests with sub-chronic assays in both genetic toxicology
and reproductive toxicology is an obvious opportunity and starting
point.
The purpose of the above recommendations is to enhance
understanding of what constitutes a germ cell mutagen. The
approaches proposed above provide a toolbox of options that
the participants recommend can be used to address the existing
gaps. In particular, there is an urgent need for a more mechanis-
tically diverse database. This will require continued integration of
germ and somatic cell genetic toxicology tests. However, the group
expressed concern over where the resources might come from to
address these various gaps and build (enhance) the database.
10.3.2. Reproductive toxicology tests
There was unanimous consent that current one-generation
and multi-generational reproductive toxicology tests provide end-
points of relevance to germ cell genotoxicity in addition to other
possible reproductive effects (e.g. endocrine effects). The relevant
endpoints noted were: (a) detrimental effects on fecundity/fertility
(number of successful litters and number of pups per litter); (b)
severe effects on sperm count; (c) altered testicular histopathol-
ogy; and (d) decreased testicular weight. It was also agreed that
alterations to sperm morphology do not provide information on
germ cell genotoxicity (but may indicate that a chemical can reach
the testes). There was consensus that if there was a significant
reduction in male reproductive performance, the chemical should
be assessed using a DLT approach (where assessment of male medi-
ated post-implantation loss is quantified after the males have been
dosed for an appropriate period of time, see Fig. 1). At its sim-
plest, this could be by mating males after they have been dosed
for all of spermatogenesis, which could be integrated with current
repeat dose toxicity tests [58] or reproductive toxicity tests. Overall,
the group recommended that an important retrospective analysis
would be to study the existing reproductive toxicology databases
in detail to mine the data on well-known compounds and identify
associations between reproductive toxicology endpoints and germ
cell mutagenesis. It was recommended that a consortium consider
this as a potential project that would be of great value to this field.
Although there was general enthusiasm for the application of
whole genome sequencing to pedigrees collected as part of stan-
dard reproductive toxicology testing, the participants noted that it
is too early to make such a recommendation and acknowledged the
need for basic research on this application first. The group unani-
mously supported the promotion of such experiments as part of
future research programs and recommended that appropriately
frozen specimens begin to be collected from standard reproduc-
tive toxicology assays for such purposes. However, modifications
to existing protocols are likely required for effective analysis of
germ cell mutations in pedigrees from reproductive toxicity assays,
which relates to the requirement to haplotype new mutations to
assign parental origin. This is difficult in inbred rodents (which
would lack the SNVs required for haplotyping) and would require
the use of two different strains in a reproductive toxicology assay.
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Finally, workshop participants noted that studies of effects in
females are a major gap. It was unanimously recommended that
maternal exposures (in utero in addition to prior to pregnancy)
should be performed more regularly and considered for future
research using whole genome sequencing. One final opportunity
that was noted by the group was the possibility of using TGR mouse
models for reproductive toxicity testing. This was acknowledged
as an opportunity but it was felt that high costs might currently
be prohibitive. However, the participants recommended further
exploring this opportunity.
11. Considerations in risk assessment
Historically, germ cell risk has been estimated quantitatively
via several rodent-based approaches: the doubling dose (indirect
method; [157]), the parallelogram method [158], and the direct
method [157], which provide estimates of relative genetic risk
rather than the frequency of affected offspring. Subsequently, a
method was developed to estimate the frequency of genetically
abnormal offspring, which provides a more realistic, quantitative
estimate of the actual risk to future generations of affected parents
[159]. These approaches relied mostly on assays that are generally
no longer used to provide data for the estimation of risk to offspring,
and required broad assumptions to extrapolate from rodents to
humans. Accordingly, new approaches for characterizing germ cell
risk must be explored. Germ cell risk assessment must rely on the
many types of tests described above that range from direct effects
on parental germ cells (e.g. aberrations or MN in spermatogonia or
spermatids; mutation of transgenes in germ cells), developmental
and reproduction tests (e.g. DLT; 1- or multi-generation reproduc-
tion studies), and effects on support cells of the germinal tissues.
Absorption, distribution, metabolism, and excretion (ADME) must
be considered to provide evidence of germ cell exposure. From most
of these studies, dose-response data can be generated for endpoints
of concern related to germ cells. These data can then be evaluated
similarly to other toxicity data using commonly accepted metrics
and mathematical models.
Probably the most useful and commonly used approach today
begins with modeling the dose-response data to generate a point of
departure (POD) metric. The POD is the point on the dose-response
curve that marks the starting point for low-dose extrapolation to
exposure levels of concern for human risk [160]. Recent evalua-
tions of appropriate models to generate PODs recommend that the
benchmark approach (see EPA, 2012 for guidance [159]) is the most
appropriate for modeling genetic toxicity data [161–164].
Once a POD is generated from the dose-response modeling on
any test data related to potential adverse germ cell effects, a charac-
terization of the mode of action (MOA) for biological understanding
of what the effects are, and how they may be adverse, is indicated.
The MOA is the sequence of key events and processes that lead to
an adverse outcome. ADME information is very useful for providing
target cell exposure data when evaluating possible MOAs. Based on
the MOA, and other relevant information, the appropriate form of
extrapolation below the POD can be employed.
If the MOA supports a linear low-dose extrapolation, then the
slope provides an estimate of risk per unit of dose. However, if a
linear extrapolation is not indicated by the MOA, either a margin
of exposure (MOE) approach, or an uncertainty factor approach, is
commonly used to generate a reference dose (RfD), depending on
the risk management needs being addressed. The MOE compares
the POD to the current or predicted human exposure (i.e. ratio of the
POD to the human exposure) to determine how close the human
exposures are to the dose (POD) associated with adverse effects. The
RfD is derived by dividing the dose at the POD by uncertainty factors
to determine a dose below which the risk becomes of low concern.
These two approaches for genetic toxicity using in vitro and in vivo
data from somatic cells are discussed more fully in Johnson et al.
[163], and can be considered valid for characterizing the risk from
germ cell-related data. Although these concepts were introduced at
the IWGT meeting, there was insufficient time for a full discussion.
However, the presently available data and current understanding of
germ cell responses to mutagens, including pharmacokinetics, and
interspecies extrapolation, do not currently offer grounds to reject
the use of these approaches for characterizing the risk to germ cells
from potential mutagens.
12. Concluding remarks
In summary, the importance of protecting humans from herita-
ble mutation hazards and risks, and the determination of the causes
of de novo mutations in offspring was emphasized in this workshop.
An updated review of the advantages and disadvantages of the
existing assay for germ cell and heritable effects highlighted a num-
ber of gaps. Various existing and new assays show great promise
to help meet these needs. Newly recognized types of genomic
changes, such as CNVs, need to be explored to understand their rele-
vance in germ cell genetic toxicology. Such tests will require further
development and validation, as well as research efforts to establish
the best integrated testing approach. We must work to enhance
the current database to identify the most effective approaches. This
effort should include harnessing available data from reproductive
toxicology assays that have not been used historically for these pur-
poses. Induced mutations that do not cause a phenotype in the first
generation must also be considered for causing disease in future
generations. Moreover, intergenerational mutational events occur-
ring by exposure of germ cells during embryologic development,
which can result in genetic disease, should also be investigated
[124,165]. Accordingly, applying new genomics technologies to
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